Evidence map›Paper›PMID 40074448›Full record

ArticleJournal, genetic engineering & biotechnology2025

Designing of multi-valent epitope vaccine displaying interactions with diverse HLA alleles against Candida auris using immuno-informatics.

Vaishali Ahlawat, Kiran Sura, Mehak Dangi, Anil Kumar Chhillar

Abstract read
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. RethinkingVaccines · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vaishali AhlawatCentre for Bioinformatics, M.D. University, Rohtak, Haryana, India.
Kiran SuraCentre for Bioinformatics, M.D. University, Rohtak, Haryana, India.
Mehak DangiCentre for Bioinformatics, M.D. University, Rohtak, Haryana, India. Electronic address: mehak.bioinfo@mdurohtak.ac.in.
Anil Kumar ChhillarCentre for Bioinformatics, M.D. University, Rohtak, Haryana, India. Electronic address: anil.chhillar@mdurohtak.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of multidrug resistanceagainst several antifungal drugs and the absence of alternate therapy limits the treatment choices leading to the spread of Candida auris infections, especially inimmunocompromised patients. This work aims to construct the multi-epitope vaccine using an immuno-informatics approachdue to the lack of efficient treatments for C. auris. Very few in-silico studies have been conducted to design a vaccine against C. auris majorly targeting the specific proteins regardless of the importance of non-structural proteins. The whole proteome was targeted to identify the antigenic proteins because components other than non-structural proteins can also potentially act as immunogens. The antigenic determinants were mapped in the target proteins and screened via IEDB analysis and prediction tools. Distinctive HLA types manifested at varied genotypic frequencies in diverse ethnicities. Therefore, to design an effectual vaccine construct, the candidate T-cell antigenic determinants were employed for population coverage. Various bioinformatics tools and servers were used for the 3D analysis of vaccine structure, including prediction, refinement, and validation. The computational validation of the molecular interaction of the proposed vaccine with TLR4, TLR5, HLA-A*11:01, and HLA-A*02:01 was done using docking studies. The docked complexes were subjected to molecular dynamics (MD) simulations to confirm their stability, compactness, and flexibility. Simulation studies demonstrated that the vaccine complexed with immune and MHC receptors was stable during the simulation time. The outcome of the current study suggests the designed vaccine can be a potential vaccine candidate and elicit the immune response against C. auris. However, experimental verification (in-vitro/in-vivo) is required to confirm the effectiveness and safety of the designed vaccine construct.

Indexed as

Candida auris dockingEpitopeImmuno-informaticsMolecular dynamics simulationReverse vaccinologyVaccine

Identifiers

PMID40074448
PMCPMC11925578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.